C.O. Bigelow Apothecaries owner wins Long Island University Distinguished Alumnus award
NEW YORK — Long Island University’s Brooklyn, N.Y., campus has given C.O. Bigelow Apothecaries owner Ian Ginsberg its Distinguished Alumnus Award, the university said.
Ginsberg received the award at the campus’ commencement ceremony at Barclays Center Thursday.
A 1985 graduate of the university’s pharmacy school and third-generation pharmacist, Ginsberg is also the chairman of the Independent Cosmetic Manufacturers and Distributors.
Hospira chief scientific officer returns
LAKE FOREST, Ill. — Hospira has reappointed its chief scientific officer after he briefly left the country earlier this year, the generic drug maker said.
Sumant Ramachandra has been reappointed to the position, effective Friday, and will be in charge of the company’s research and development, regulatory and medical affairs.
"Under Sumant’s leadership, Hospira has established one of the most robust biosimilars pipelines in the industry, expanded an already market-leading generic injectables portfolio and built a talented scientific, medical and regulatory organization to execute our vision for future success. While we had interviewed an exceptional slate of candidates for this role, we determined that Sumant remained not only the best fit, but also would be best positioned to seamlessly advance our R&D priorities."
FDA advisory committee to meet in July on opioid painkiller
SYDNEY — A Food and Drug Administration panel will consider whether to recommend approval for an experimental painkiller in July, the drug’s developer said Friday.
Australia-based QRxPharma said the FDA had determined that an advisory committee would meet on July 17 to consider a resubmitted application for Moxduo, an immediate-release formulation of the opioid painkillers morphine and oxycodone.
The company has sought approval for the drug since summer 2011, and the FDA has indicated it will decide whether or not to approve it in August 2013. The agency is not required to follow advisory committee recommendations in deciding whether or not to approve a drug, but usually does.